Antiplatelet and antithrombotic treatment for secondary prevention in ischaemic heart disease

M. Lettino, S. Leonardi, E. De Maria, S. Halvorsen

Research output: Contribution to journalArticle

Abstract

Platelets play a key role in the pathogenesis of acute coronary syndromes and this is why antiplatelet drugs are essential, both in the acute phase and in the long-term follow-up in preventing recurrent myocardial infarction, stroke and cardiovascular death. Aspirin is the most used agent and still remains the first choice drug for lifelong administration in secondary prevention after myocardial infarction. Dual antiplatelet therapy, targeting more than one pathway of platelet activation, has significantly improved the outcome of patients with acute coronary syndromes despite an increased risk of bleeding complications. The aim of this article is to provide an overview of the evidence from randomized clinical trials with a focus on the best association between aspirin and a P2Y12 inhibitor such as clopidogrel, prasugrel or ticagrelor, on the selection of the appropriate agent based on the revascularization strategy and on the optimal duration of such an intensive treatment. We will also provide the latest evidence regarding new antithrombotic agents, such as vorapaxar or low dose rivaroxaban, that could be associated with dual antiplatelet therapy in high risk patients with the aim of further reducing the rate of major ischaemic complications. Finally we will address the issue of patients presenting with atrial fibrillation and a concomitant acute coronary syndrome who frequently need a percutaneous coronary intervention, with a specific focus on the combination therapy of antiplatelet and anticoagulant agents and on the current recommendations of the guidelines.
Original languageEnglish
Pages (from-to)61-70
Number of pages10
JournalEuropean Journal of Preventive Cardiology
Volume24
Issue number3_suppl
DOIs
Publication statusPublished - Jun 1 2017

Fingerprint

Secondary Prevention
Myocardial Ischemia
Acute Coronary Syndrome
clopidogrel
Platelet Aggregation Inhibitors
Myocardial Infarction
Aspirin
Fibrinolytic Agents
Platelet Activation
Percutaneous Coronary Intervention
Therapeutics
Anticoagulants
Atrial Fibrillation
Blood Platelets
Randomized Controlled Trials
Guidelines
Hemorrhage
Pharmaceutical Preparations

Keywords

  • Dual antiplatelet therapy
  • aspirin
  • clopidogrel
  • prasugrel
  • rivaroxaban
  • ticagrelor
  • vorapaxar

Cite this

Antiplatelet and antithrombotic treatment for secondary prevention in ischaemic heart disease. / Lettino, M.; Leonardi, S.; Maria, E. De; Halvorsen, S.

In: European Journal of Preventive Cardiology, Vol. 24, No. 3_suppl, 01.06.2017, p. 61-70.

Research output: Contribution to journalArticle

@article{bfa1f84ab16c4dd38fb5ade1da0c7ac9,
title = "Antiplatelet and antithrombotic treatment for secondary prevention in ischaemic heart disease",
abstract = "Platelets play a key role in the pathogenesis of acute coronary syndromes and this is why antiplatelet drugs are essential, both in the acute phase and in the long-term follow-up in preventing recurrent myocardial infarction, stroke and cardiovascular death. Aspirin is the most used agent and still remains the first choice drug for lifelong administration in secondary prevention after myocardial infarction. Dual antiplatelet therapy, targeting more than one pathway of platelet activation, has significantly improved the outcome of patients with acute coronary syndromes despite an increased risk of bleeding complications. The aim of this article is to provide an overview of the evidence from randomized clinical trials with a focus on the best association between aspirin and a P2Y12 inhibitor such as clopidogrel, prasugrel or ticagrelor, on the selection of the appropriate agent based on the revascularization strategy and on the optimal duration of such an intensive treatment. We will also provide the latest evidence regarding new antithrombotic agents, such as vorapaxar or low dose rivaroxaban, that could be associated with dual antiplatelet therapy in high risk patients with the aim of further reducing the rate of major ischaemic complications. Finally we will address the issue of patients presenting with atrial fibrillation and a concomitant acute coronary syndrome who frequently need a percutaneous coronary intervention, with a specific focus on the combination therapy of antiplatelet and anticoagulant agents and on the current recommendations of the guidelines.",
keywords = "Dual antiplatelet therapy, aspirin, clopidogrel, prasugrel, rivaroxaban, ticagrelor, vorapaxar",
author = "M. Lettino and S. Leonardi and Maria, {E. De} and S. Halvorsen",
note = "LR: 20170616; JID: 101564430; OTO: NOTNLM; 2017/06/17 06:00 [entrez]; 2017/06/18 06:00 [pubmed]; 2017/06/18 06:00 [medline]; ppublish",
year = "2017",
month = "6",
day = "1",
doi = "10.1177/2047487317707854 [doi]",
language = "English",
volume = "24",
pages = "61--70",
journal = "European Journal of Preventive Cardiology",
issn = "2047-4873",
publisher = "SAGE Publications Ltd",
number = "3_suppl",

}

TY - JOUR

T1 - Antiplatelet and antithrombotic treatment for secondary prevention in ischaemic heart disease

AU - Lettino, M.

AU - Leonardi, S.

AU - Maria, E. De

AU - Halvorsen, S.

N1 - LR: 20170616; JID: 101564430; OTO: NOTNLM; 2017/06/17 06:00 [entrez]; 2017/06/18 06:00 [pubmed]; 2017/06/18 06:00 [medline]; ppublish

PY - 2017/6/1

Y1 - 2017/6/1

N2 - Platelets play a key role in the pathogenesis of acute coronary syndromes and this is why antiplatelet drugs are essential, both in the acute phase and in the long-term follow-up in preventing recurrent myocardial infarction, stroke and cardiovascular death. Aspirin is the most used agent and still remains the first choice drug for lifelong administration in secondary prevention after myocardial infarction. Dual antiplatelet therapy, targeting more than one pathway of platelet activation, has significantly improved the outcome of patients with acute coronary syndromes despite an increased risk of bleeding complications. The aim of this article is to provide an overview of the evidence from randomized clinical trials with a focus on the best association between aspirin and a P2Y12 inhibitor such as clopidogrel, prasugrel or ticagrelor, on the selection of the appropriate agent based on the revascularization strategy and on the optimal duration of such an intensive treatment. We will also provide the latest evidence regarding new antithrombotic agents, such as vorapaxar or low dose rivaroxaban, that could be associated with dual antiplatelet therapy in high risk patients with the aim of further reducing the rate of major ischaemic complications. Finally we will address the issue of patients presenting with atrial fibrillation and a concomitant acute coronary syndrome who frequently need a percutaneous coronary intervention, with a specific focus on the combination therapy of antiplatelet and anticoagulant agents and on the current recommendations of the guidelines.

AB - Platelets play a key role in the pathogenesis of acute coronary syndromes and this is why antiplatelet drugs are essential, both in the acute phase and in the long-term follow-up in preventing recurrent myocardial infarction, stroke and cardiovascular death. Aspirin is the most used agent and still remains the first choice drug for lifelong administration in secondary prevention after myocardial infarction. Dual antiplatelet therapy, targeting more than one pathway of platelet activation, has significantly improved the outcome of patients with acute coronary syndromes despite an increased risk of bleeding complications. The aim of this article is to provide an overview of the evidence from randomized clinical trials with a focus on the best association between aspirin and a P2Y12 inhibitor such as clopidogrel, prasugrel or ticagrelor, on the selection of the appropriate agent based on the revascularization strategy and on the optimal duration of such an intensive treatment. We will also provide the latest evidence regarding new antithrombotic agents, such as vorapaxar or low dose rivaroxaban, that could be associated with dual antiplatelet therapy in high risk patients with the aim of further reducing the rate of major ischaemic complications. Finally we will address the issue of patients presenting with atrial fibrillation and a concomitant acute coronary syndrome who frequently need a percutaneous coronary intervention, with a specific focus on the combination therapy of antiplatelet and anticoagulant agents and on the current recommendations of the guidelines.

KW - Dual antiplatelet therapy

KW - aspirin

KW - clopidogrel

KW - prasugrel

KW - rivaroxaban

KW - ticagrelor

KW - vorapaxar

U2 - 10.1177/2047487317707854 [doi]

DO - 10.1177/2047487317707854 [doi]

M3 - Article

VL - 24

SP - 61

EP - 70

JO - European Journal of Preventive Cardiology

JF - European Journal of Preventive Cardiology

SN - 2047-4873

IS - 3_suppl

ER -